Navigation Links
Nuvasive Reports Third Quarter 2008 Financial Results
Date:10/22/2008

p>

Low High

GAAP net loss per share (A) $(0.82) $(0.80)

In-process research and

development (IPR&D) (C) 0.58 0.58

Other adjustments (F) 0.29 0.29

Earnings per share excluding

IPR&D and other adjustments 0.05 0.07

Stock-based compensation (B) 0.56 0.56

Amortization of acquired

intangible assets (D) 0.09 0.09

Non-GAAP earnings per share (A) $0.70 $0.72

Shares used in computing GAAP

net loss per share (A) 35,800 35,800

Shares used in computing

non-GAAP net loss per share

(A) 37,600 37,600

A -- GAAP net loss per share is calculated using basic weighted shares outstanding; Non-GAAP earnings per share is calculated using diluted weighted shares outstanding.

B -- Non-cash stock-based compensation.

C -- Charges related to the acquisition of the pedicle screw technology in the first quarter of 2008 and the acquisition of the Osteocel Business Unit in the third quarter of 2008.

D -- Amortization of purchased technology assets.

E -- Other adjustments related to the one-time leasehold termination charge of $4.8 million, transitional support costs of $2.6 million related to the Company's ERP system and $0.6 million for intellectual property litigation expenses.

F -- Other adjustments related to the one-time leasehold termination charge of $4.8 million, transitional support costs of $4.1 million related to the Company's ERP system and $1.6 million for intellectual property litigation expenses.

Conference Call

NuVasive will hold a conference call today at 5:30
'/>"/>

SOURCE NuVasive, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. NuVasive to Present at Morgan Stanley Global Healthcare Unplugged Conference
2. NuVasive Completes Acquisition of Osteocel Biologics Business
3. NuVasive Announces Web Cast and Conference Call of Second Quarter 2008 Results
4. NuVasive to Present at William Blair 28th Annual Growth Stock Conference
5. NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics
6. NuVasive to Present at Lehman Brothers Eleventh Annual Global Healthcare Conference
7. NuVasive to Present at Canaccord Adams Small-Cap Orthopedics Conference
8. NuVasive Announces Webcast and Conference Call of Fourth Quarter and Full Year 2007 Results
9. NuVasive to Host Investor Reception on September 11, 2007
10. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
11. Sangui Biotech International, Inc., Reports Sales Decrease, Continued Losses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... , March 30, 2015  NuGene International, ... subsidiary corporation, NuGene BioPharma, Inc. has added another ... Dr. Guan is an internationally recognized researcher ... his college education at Peking University, ... degree from the University of North Carolina, Chapel ...
(Date:3/30/2015)... ROCKVILLE, Md. , March 30, 2015 ... company dedicated to the acquisition, development and commercialization of ... for the global market with a commercial focus on ... China Food and Drug Administration (CFDA) has approved the ... trial in ovarian clear cell carcinoma (OCCC) patients for ...
(Date:3/30/2015)... , March 30, 2015  Spherix Incorporated (Nasdaq: ... to the fostering and monetization of intellectual property, ...  Case No. 3:13-cv-03494-M and  Spherix v. Uniden , ... District Court for the Northern District of ... Spherix v. Verizon, Case No. 1:14-cv-00721-GBL-TCB, ...
(Date:3/30/2015)... N.J. , March 30, 2015  Naldemedine, ... under development by Shionogi & Co., Ltd., met ... III study (COMPOSE I) for the treatment of ... non-cancer pain receiving opioid therapy. Study results showed ... statistically significantly improved the frequency of spontaneous bowel ...
Breaking Biology Technology:UCI Professor Zhibin Guan Joins NuGene Advisory Board 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 2Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 3Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3
... , CINCINNATI, Sept. 16 Kendle (Nasdaq: ... the Company will participate in the upcoming UBS Global Life Sciences ... Hotel in New York City. , , (Logo: ... Kendle,s formal presentation will be given by Chairman and Chief ...
... ... other technologies for professional purposes and treatment decisions , ... New York, NY (PRWEB) September 16, 2009 -- ... biotech, and device corporate and product websites on a regular basis, according to pharmaceutical ...
... SOUTH SAN FRANCISCO, Calif., Sept. 16 Poniard ... focused on innovative oncology therapies, today announced that Jerry McMahon, ... overview at the 2009 UBS Global Life Sciences Conference on ... the Grand Hyatt Hotel in New York City. , ...
Cached Biology Technology:Kendle to Present at UBS Global Life Sciences Conference 2Oncologists Visit Pharma Sites and Post Professional Content Online More Frequently than the Average Physician 2Oncologists Visit Pharma Sites and Post Professional Content Online More Frequently than the Average Physician 3Oncologists Visit Pharma Sites and Post Professional Content Online More Frequently than the Average Physician 4Poniard Pharmaceuticals to Present at the 2009 UBS Global Life Sciences Conference 2
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and ... addition of the "Global Iris Recognition Market 2015-2019" ... forecast the Global Iris Recognition market to grow at ... This report covers the present scenario and ... for the period 2015-2019. To calculate the market size, ...
(Date:3/23/2015)... NEW YORK , March 23, 2015   ... digital property management company, today announced that the Company ... platform for both enterprise and consumers at Connect:ID on ... D.C. HOYOS Labs will highlight the IEEE ... 1U TM ; and enterprise access control system. ...
(Date:3/20/2015)... Conn. , March 20, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... smart wallet is one of the products featured in ... March 20th at 11:00 PM EST on the DIY ... to Las Vegas , site of ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3
... When prehistoric fish made their first forays onto land, ... in the online open access journal, BMC Evolutionary Biology, ... viewed their new environment in full colour. A ... Biomedical Sciences, University of Queensland, Brisbane, Australia, analysed retinas ...
... been uncovered from old experiments by researchers at the ... Hospital. The finding suggests that useful information about many ... data. "We,ve devised a fairly simple way to ... disease genes for further genetic study," said Atul Butte, ...
... Severely restricting calories leads to a longer life, scientists ... the first time that such a diet also can ... inevitable progression to physical disability and loss of independence. ... restriction, showed that the diet reduces the amount of ...
Cached Biology News:Stanford/Packard researchers find disease genes hidden in discarded data 2Stanford/Packard researchers find disease genes hidden in discarded data 3Severely restricted diet linked to physical fitness into old age 2
Artisan™ Wash Solution (x 50) Additional Information: EU regulatory status: CE US regulatory status: IVD ...
... Gene Cycler unit is an inexpensive personal or ... the PCR process. Lightweight, with a small footprint, ... anywhere, including the researcher's desk. , The Gene ... who do not have access to a large ...
... The IHC Select Immunophosphatase Secondary Detection System ... IHC Select Prediluted Primary Antibody reagents, which ... qualitative identification of antigens by light microscopy ... Secondary Detection System may also be used ...
... RNA stain is used to stain and ... agarose gels and does not interfere with ... nm transilluminator, the stain emits a red-orange ... film or with a CCD camera-based gel ...
Biology Products: